Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) is a diagnostic tool to evaluate metabolic activity by measuring accumulation of FDG, an analogue of glucose, and has been widely used for detecting small tumors, monitoring treatment response and predicting patients' prognosis in a variety of cancers. However, the molecular mechanism of FDG accumulation into tumors remains to be investigated. It is well-known that most cancers are metabolically active with elevated glucose metabolism, a phenomenon known as the Warburg effect. The underlying mechanisms for elevated glucose metabolism in cancer tissues are complex. Recent reports have indicated the potential of FDG-PET/CT scans in predicting mutational status (e.g. , KRAS gene mutation) of colorectal cancer (CRC), which suggests that FDG-PET/ CT scans may play a key role in determining therapeutic strategies by non-invasively predicting treatment response to anti-epidermal growth factor receptor (EGFR) therapy. In this review, we summarize the current findings investigating the molecular mechanism of 18 F-FDG accumulation in CRC.
INTRODUCTION
Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (FDG) is a imaging method used for detecting small tumors, monitoring treatment response and predicting patients' prognosis in a variety types of cancers [1, 2] . This technique is based on evaluating tissue glucose metabolism by measuring accumulated FDG, a glucose analogue. FDG is incorporated into the cell through glucose transporters (GLUTs), and then phosphorylated by hexokinases (HXKs) to FDG-6-phosphate, which becomes stored within the cell. There is no standardized approach for quantitative measurement of 18 F-FDG accumulation yet, although the 18 F-FDG maximum standardized uptake value (SUVmax) is commonly considered as a barometer of tumor viability. In addition to SUVmax, there are some 18 F-FDG uptake-related quantitative parameters: SUVmean (average SUV within the tumor), SUVpeak (peak SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), etc.
Most cancer cells are preferential to metabolize glucose by glycolysis, even in the presence of oxygen, so-called "aerobic glycolysis (Warburg effect)" [3, 4] . This increased glucose metabolism accounts for 18 F-FDG accumulation into cancer cells, which results in the positive signals in FDG-PET/CT scans. However, the mechanisms how 18 F-FDG is accumulated into cancer tissues are complex [5] [6] [7] . These factors are divided into tumor-related (e.g., glucose metabolism, histological differentiation, vascular factor, tumor size and hypoxia) and non-tumor-related components (e.g., high serum glucose level and local inflammation). 18 F-FDG is not specifically accumulated into cancer; it can also be accumulated into inflammatory sites as well. In spite of its clinical usefulness, the cellular and molecular mechanisms of 18 F-FDG accumulation have not yet been elucidated so far.
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancerrelated deaths in the world, with the majority attributable to distant metastases [8] . In spite of great advance in systemic treatment of metastatic CRC, the overall 5-year patient survival has remained lamentably low, below 10%. CRC is progressively promoted through multistep carcinogenesis of accumulated genetic changes in oncogenes and tumor suppressor genes. Most adenomas are initiated by inactivation of the APC gene, and then progress into adenocarcinomas through accumulation of additional alterations in the KRAS, TP53 and SMAD4 genes, etc [9] . In this context, this review summarizes the current literatures investigating the molecular mechanisms how 18 F-FDG is accumulated into CRC.
GLUCOSE TRANSPORTERS AND HEXOKINASES
A line of literatures have demonstrated that 18 F-FDG accumulation in cancer cells depends largely on two classes of proteins: Glucose transporters (GLUT) and Hexokinases (HXKs) [10] . 18 F-FDG is incorporated into the cell via a family of 14 facilitative GLUTs, and then phosphorylated by HXKs to FDG-6-phosphate, which becomes stored within the cell, because of its negative charge. The up-regulation of GLUTs is commonly occurred in most cancers and is associated with poor prognosis of patients. Although different types of tumors have distinct expressions of different GLUTs, GLUT1 up-regulation is common in most cancers and is linked to tumor stage and prognosis [11, 12] . In addition, increased levels of HXK (primarily, HXK2 of the 4 types) occur in many cancers [13, 14] . HXK2 binds to the mitochondria membrane and efficiently phosphorylates FDG to FDG-6-phosphate. 18 F-FDG accumulation depends largely on GLUT1 and the rate-limiting glycolytic enzyme, HXK2, in most types of cancers, although other GLUT proteins (e.g., GLUT3) and other enzymes downstream of HXK (e.g., pyruvate dehydrogenase kinase 1) may be involved [10] . While the combined expression of GLUT1 and HXK2 likely plays some role in determining 18 F-FDG accumulation, the presence and strength of these associations seem to vary among tumor types, and conclusive evidence for one protein playing a dominant role is lacking. Although the molecular mechanisms of 18 F-FDG accumulation into CRC are not as well-analyzed as in breast and lung cancers, several studies indicate that, in CRC, an increase of GLUT1 expression is more essential for 18 F-FDG accumulation than HXK activity [10, 15] .
KRAS mutations in the KRAS gene in CRCs
Oncogenic activation of KRAS affects several cellular functions that regulate morphology, proliferation, and motility. KRAS mutations occur in a variety of human malignancies, most frequently in pancreatic cancer, nonsmall cell lung cancer (NSCLC) and CRCs. In particular, KRAS mutations occur in approximately 40% of CRCs; mutations of codon 12 or 13 occur in more than 90% of the cases. The RAS gene family encodes membranebound guanosine triphosphate (GTP) proteins that interact with several metabolic pathways, such as mitogenactivated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K). Activating RAS mutations alter the activity of GTPase, inducing constitutive activation of RAS pathway. A number of clinical studies indicate that KRAS mutations can predict a lack of response to anti-epidermal growth factor receptor (EGFR) therapy [16, 17] . The anti-EGFR antibodies (cetuximab and panitumumab) are now recommended only for CRCs with wild-type KRAS, although a wild-type KRAS gene does not guarantee a response. Therefore, mutational testing of the KRAS gene, using biopsied or resected tissues, is incorporated into routine clinical practice. However, one limitation is the heterogeneity of KRAS mutational status, which can either be intratumoral heterogeneity within a primary CRC [18] , or discordant KRAS status between a primary CRC and its corresponding metastatic CRC [19, 20] . Another limitation is failure to judge KRAS status due to poor quality of extracted DNA. In addition, it is not always easy to extract the samples from metastatic CRCs due to limited access and invasive procedures. Therefore, alternative non-invasive tool to predict the mutation profile, such as 18 F-FDG PET scans, could help overcome these limitations.
Association between KRAS mutations and 18 F-FDG accumulation
There is recent preclinical evidence that KRAS mutations are associated with increased expression of GLUT1. Studies with isogeneic CRC cell lines indicated a significant increase in glucose uptake caused by GLUT1 up-regulation, which is prominent in CRC cells with mutant KRAS alleles, providing them with a growth advantage in low glucose environment [21] . In a retrospective analysis (n = 51), we previously found that SUVmax and tumor-to-liver ratio (TLR) were significantly higher in primary CRCs with mutated KRAS than in those with wild-type KRAS, and that SUVmax exhibited an odds ratio (OR) of 1.17 with an accuracy of 75% in predicting KRAS status when using a cutoff value of 13 [22] . This was the first clinical report to show the causal relationship between KRAS mutations and 18 F-FDG accumulation in a variety of cancer. Following this report, some other groups have also shown that 18 F-FDG accumulation can reflect KRAS mutational status in CRC and NSCLC (Table 1) . Using a larger size of sample (n = 121), Chen et al [23] investigated the association between 18 F-FDG uptake-related parameters and KRAS mutational status, and found that SUVmax and TW40% (a 40% threshold level of SUVmax for tumor width (TW) were 2 predictors for KRAS mutations of CRC. Receiver operating characteristics analysis revealed that the accuracy of SUVmax was highest (70%) with a cutoff value of 11, and that the TW40% method could achieve higher accuracy (71.4%) when focusing on rectal cancer. Miles et al [24] reported that multifunctional imaging with PET/CT and recursive decision-tree analysis to combine measurements of tumor 18 F-FDG uptake (SUVmax), CT texture (expressed as mean of positive pixels) and blood perfusion (measured by dynamic contrast-enhanced CT) enabled to identify CRCs with KRAS mutations showing hypoxic or proliferative phenotypes. This exploratory study with 33 CRC patients indicated that the true-positive rate, false-positive rate and accuracy of the decision tree were 82.4% (63.9%-93.9%), 0% (0%-10.4%) and 90.1% (79.2%-96.0%), respectively. The accuracy of SUVmax could be improved when combined with other imaging features: SUVmax, CT texture and perfusion. Lee et al [25] investigated the relationship between 18 F-FDG uptakerelated parameters (e.g., SUVmax, SUVpeak, MTV and TLG), KRAS mutations and C-reactive protein (CRP) with 179 CRC cases. Multivariate analysis demonstrated that SUVmax and SUVpeak are significantly associated with KRAS mutational status (OR, 3.3, P = 0.005 and OR, 3.9, P = 0.004, respectively) together with histological findings and lymph node metastasis. 18 F-FDG accumulation was significantly higher in CRCs with mutated KRAS and normal CRP levels. CRCs with high CRP levels (> 6.0 mg/L; n = 47) was correlated to larger tumor size, higher SUVmax, higher SUVpeak, higher MTV and higher TLG, compared to those with low CRP levels (< 6.0 mg/L; n = 132), which indicates that local inflammation with high CRP levels could affect 18 F-FDG quantification in CRC tumors.
However, the clinical benefit of above findings was limited, because endoscopic biopsy for KRAS mutational testing is easy in primary CRC. Importantly, we have recently examined whether a similar relationship can exist in metastatic CRC [26] . In a retrospective analysis with 55 metastatic CRC tumors, we found that SUVmax was not associated with KRAS mutational status. However, when focusing on tumors larger than 10 mm in order to remove the partial volume effect, SUVmax was significantly higher in CRCs with mutated KRAS than in those with wild-type KRAS (8.3 ± 4.1 and 5.7 ± 2.4, respectively; P = 0.03). KRAS status of metastatic CRC was predicted with an accuracy of 71.4% when using a SUVmax cutoff value of 6.0. This is the first clinical study showing a causal relationship between 18 F-FDG accumulation and KRAS mutations in metastatic CRC, which indicates that FDG-PET/CT scans might determine therapeutic strategies by predicting treatment response to anti-EGFR therapy. Meanwhile, Krikelis et al [27] reported a lack of association between 18 F-FDG accumulation and KRAS mutational status of metastatic CRC. Although sample size and ethnic differences might be sources of the bias, we suppose that the lack of association may be due to improper patient selection. In other clinical studies, patients with high serum glucose levels, smallsized tumors or high CRP levels were excluded, because these variables interfere with 18 F-FDG accumulation. In genetically engineered mouse models (GEMM)-derived orthotopic transplant models of CRC, subcutaneous tumors from KRAS-mutant APC -/-TP53 -/-CRC cells produced a significantly higher 18 F-FDG PET signal compared to KRAS-wild-type APC -/-TP53 -/-CRC cells [28] . Oncogenic KRAS promotes an increase in cellular glucose uptake and lactate production in vitro and in vivo.
Regarding NSCLC (n = 102), Caicedo et al [29] found that NSCLC tumors harboring KRAS mutations exhibited significantly higher 18 F-FDG accumulation than those with wild-type KRAS, although no associations between different EGFR mutation types and 18 F-FDG uptake were found. The sensitivity and specificity of KRAS mutational status were 78.6% and 62.2%, respectively, with a diagnostic accuracy of 66.7%. A multivariate model with stage, gender, age and SUVmean could predict KRAS mutational status in stage Ⅲ or Ⅳ. A recent study using GEMM of lung cancer reported that mice harboring lung tumors with KRAS and LKB1 or TP53 mutations showed Kawada K et al .
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F-FDG accumulation and CRC significantly higher 18 F-FDG accumulation than those with only KRAS mutations [30] . Taken together, FDG-PET/CT scans could predict KRAS mutational status in a variety of human KRAS-related cancers (CRC, NSCLC, pancreatic cancer, etc.).
HYPOXIA
The relationship between glucose metabolism and tumor growth can be explained by adaptation to hypoxia through up-regulation of GLUTs as well as the translocation and increased enzymatic activity of HXK [31] . Hypoxia-inducible factor-1α (HIF-1α) mediates cellular response to hypoxia, such as glucose metabolism and angiogenesis. Under hypoxic conditions, HIF-1α accelerates glycolysis by upregulation of inducing glucose transporters and some enzymes [32] . Some researchers have reported that there is a synergistic interaction between hypoxia, mutated KRAS and GLUT1 expression [33] [34] [35] [36] . When CRC cells were cultured in vitro under hypoxia, mutated KRAS increased the translation of HIF-1α by the PI3K pathway [33] . In addition, hypoxia or HIF-1α could also increase mutated KRAS activity, which indicate that there is a positive feedback between KRAS pathway and hypoxia [36] . Hypoxia can boost expression levels of GLUT1 through HIF-1α [35] . We have recently reported that mutated KRAS causes higher 18 F-FDG accumulation by up-regulation of GLUT1 and at least partially by induction of HIF-1α under hypoxia [37] . We also examined 51 clinical CRC samples, and found that KRAS mutational status was significantly associated with SUVmax and with GLUT1 expression, but not with HXK2 expression [21, 35] . These data suggest that 18 F-FDG accumulation observed in FDG-PET scans could reflect elevated glucose metabolism by mutated KRAS and hypoxia.
Goh et al [38] investigated the in vivo flow-metabolic phenotype by integrated 18 F-FDG PET/perfusion CT and its relationship to histopathological findings with 45 primary CRCs. The flow-metabolic ratio was significantly lower for CRCs with high expressions of VEGF or HIF-1α compared to CRCs with lower expression, which indicated that CRCs with a low-flow-high-metabolism phenotype reflected a more angiogenic phenotype. With breast cancer cell lines, Smith et al [39] reported that hypoxia upregulated GLUT1 and 6-phosphofructo-2-kinase (PFK) involved in glucose transport and glycolysis, and that these changes were induced by HIF-1α up-regulation and AMP-activated protein kinase (AMPK) activation. Preclinical studies have reported a correlation between 18 F-FDG accumulation and tumor hypoxia detected by pimonidazole [40] or 18 F-fluoromisonidazole (FMISO) [41] , a PET tracer designed to identify hypoxic cells. Similarly, some studies noted a correlation between 18 F-FDG and 18 F-FMISO retention in a clinical setting [42, 43] .
ONCOGENE PATHWAY ACTIVATION
Using GEMM, Alvarez et al [44] investigated 18 F-FDG accumulation in tumors driven by c-Myc, HER2/neu, Akt1, Wnt1 or H-RAS oncogenes, and found that 18 F-FDG accumulation was correlated positively with HXK2 and HIF-1α, and negatively with PFK2b and p-AMPK. The correlation between HXK2 and 18 F-FDG accumulation was not dependent on all variables tested, indicating that HXK2 could independently predict 18 F-FDG accumulation in this model. In contrast, GLUT1 expression was associated with 18 F-FDG accumulation only in tumors driven by Akt1 or HER2/neu. These above results demonstrated that the oncogenic pathway was a determinant of 18 F-FDG accumulation mediated by glycolytic enzymes. Moreover, certain oncogenes such as Src and c-Myc, as well as elements of the PI3K/Akt pathway, can be associated with activated glycolysis [45] [46] [47] . Tian et al [48] investigated the correlations between SUVmax and expressions of GLUT1, hepatocyte growth factor (HGF) and vascular endothelial growth factor-C (VEGF-C) in 33 CRC patients, and found that there was a significant differences in SUVmax among CRCs expressing GLUT1, HGF, c-Met and VEGF-1. Choi et al [49] investigated the correlations between SUVmax and EGFR expression with 132 CRC patients, and found that SUVmax was significantly lower in EGFR-non-expressing tumors than in EGFR-expressing tumors (10.0 ± 4.2 vs 12.1 ± 2.1; P = 0.012). At the SUVmax threshold of 7.5, the sensitivity and specificity for predicting EGFR expression were 84.9% and 40.4%, which indicated SUVmax had a limited role in Kawada K et al .
18
F-FDG accumulation and CRC predicting EGFR expression. In preclinical murine models with tumor xenografts, Ma et al [50] reported that 18 F-FDG PET accumulation was correlated with activated Akt and cellular membrane-bound GLUT1, and that the FDG-PET response did not correlate with the tumor growth response during mammalian target of rapamycin (mTOR) inhibitor therapy.
HUMAN CYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUS
It has been debated whether human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are involved in rectal cancer. Sole et al [51] reported that patients with HCMV/EBV co-infection had a significantly higher SUVmax than patients without viral co-infection, when analyzing 37 rectal cancer patients (P = 0.02). KRAS wild-type status was significantly more frequently observed in patients with EBV and HCMV/EBCV co-infection.
F-BOX AND WD REPEAT DOMAIN-CONTAINING 7
F-box and WD repeat domain-containing 7 (FBW7) is a E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRC. In CRC, it was recently reported that FBW7 targets CDX2 (caudal-related homeobox transcription factor 2) for degradation via two cdc42-phosphoclegron motifs in a GSK3beta-dependent manner [52] . Ji et al [53] have recently reported that KRAS mutations inhibit the tumor suppressor FBW7, which negatively regulates glucose metabolism by targeting the c-Myc/TXNIP (thioredoxin binding protein) axis in pancreatic cancer. The expression level of FBW7 was negatively associated with PET/CT SUVmax in 60 pancreatic cancer patients, indicating that FBW7 is an important KRAS downstream effector and might reverse KRAS-driven metabolic change.
LACTATE DEHYDROGENASE A
Lactate dehydrogenase A (LDHA) converts pyruvate to lactate and is overexpressed in many cancers [54] . Upregulation of LDHA ensures efficient glycolytic metabolism for tumor cells and reduces oxygen dependency [55] . In a retrospective analysis of 51 lung adenocarcinomas, Zhou et al [56] reported that SUVmax was significantly higher in the LDHA high-expression group than the LDHA lowexpression group (P = 0.018). GLUT1 expression in lung adenocarcinomas was significantly associated with 18 F-FDG accumulation and LDHA expression, whereas HXK2 expression was not. In CRC, it was recently reported that LDHA negatively regulated by miRNAs promotes aerobic glycolysis [57] .
PROLIFERATION-ASSOCIATED ANTIGEN

KI-67
According to a meta-analysis (81 studies, 3242 patients), Deng et al [58] reported that the relationship between 18 F-FDG accumulation and Ki-67 expression was significant in thymic epithelial tumors, gastrointestinal stromal tumors (GISTs), moderate in breast, lung and pancreatic cancers, and average in CRCs, and poor in thyroid and gastric cancers.
CONCLUSION
For prediction of KRAS mutations in CRC, the overall accuracy of SUVmax alone has only been found to be modest, ranging from 60% to 75%, although the accuracy could be improved when combined with other clinicopathologic or imaging parameters. New targeted therapies are being developed for tumors that selectively express KRAS mutations [59] . Hence, the availability of non-invasive methods, such as molecular imaging, for predicting KRAS mutational status could have considerable clinical relevance, because of their potential to improve the assessment of other molecular alterations in the future. Future advances in PET radiotracers may increase the sensitivity and specificity of this technique to provide full molecular assessment of CRC.
